Results from Phase 2 PEARL-I study in genotype 4 chronic hepatitis C patients

Share this content:
Results from Phase 2 PEARL-I study in genotype 4 chronic hepatitis C patients
Results from Phase 2 PEARL-I study in genotype 4 chronic hepatitis C patients
AbbVie has announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR) after taking AbbVie's investigational treatment with ribavirin (RBV).
READ FULL ARTICLE From Medical News Today
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »